Tekla Capital Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-42,965
| Closed | -$108K | – | 231 |
|
|
2020
Q2 | $108K | Hold |
42,965
| – | – | ﹤0.01% | 218 |
|
|
2020
Q1 | $55K | Hold |
42,965
| – | – | ﹤0.01% | 213 |
|
|
2019
Q4 | $121K | Sell |
42,965
-1
| -0% | -$3 | ﹤0.01% | 208 |
|
|
2019
Q3 | $229K | Hold |
42,966
| – | – | 0.01% | 180 |
|
|
2019
Q2 | $413K | Hold |
42,966
| – | – | 0.02% | 186 |
|
|
2019
Q1 | $1.15M | Hold |
42,966
| – | – | 0.05% | 155 |
|
|
2018
Q4 | $971K | Hold |
42,966
| – | – | 0.04% | 166 |
|
|
2018
Q3 | $2.37M | Hold |
42,966
| – | – | 0.09% | 142 |
|
|
2018
Q2 | $3.07M | Hold |
42,966
| – | – | 0.12% | 114 |
|
|
2018
Q1 | $2.64M | Hold |
42,966
| – | – | 0.1% | 123 |
|
|
2017
Q4 | $5.41M | Hold |
42,966
| – | – | 0.21% | 86 |
|
|
2017
Q3 | $5.88M | Sell |
42,966
-7,250
| -14% | -$970K | 0.21% | 81 |
|
|
2017
Q2 | $7.16M | Hold |
50,216
| – | – | 0.27% | 72 |
|
|
2017
Q1 | $9.23M | Buy |
50,216
+40,600
| +422% | +$4.55M | 0.36% | 62 |
|
|
2016
Q4 | $775K | Hold |
9,616
| – | – | 0.03% | 134 |
|
|
2016
Q3 | $737K | Hold |
9,616
| – | – | 0.03% | 136 |
|
|
2016
Q2 | $827K | Hold |
9,616
| – | – | 0.03% | 147 |
|
|
2016
Q1 | $890K | Hold |
9,616
| – | – | 0.04% | 131 |
|
|
2015
Q4 | $1.93M | Buy |
+9,616
| New | +$1.92M | 0.07% | 122 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 147 |
|
Tekla Capital Management's TTPH Position: Q3 2020 in Review
Tekla Capital Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2020, closing a stake of 42,965 shares — an estimated $108K sold.
Tekla Capital Management first reported a position in TTPH in Q4 2015 and held it in 19 quarters. The position peaked at $9.23M in Q1 2017. 1 fund tracked by Wall St. Rank holds TTPH as of Q3 2020.
- Tekla Capital Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Tekla Capital Management sold 42,965 Tetraphase Pharmaceuticals, Inc. shares in Q3 2020, an estimated $108K.
- Tekla Capital Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2015 and held it in 19 quarters.
- Tekla Capital Management's Tetraphase Pharmaceuticals, Inc. position peaked at $9.23M in Q1 2017.
- 1 fund tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2020.
Based on Tekla Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.